Akebia Therapeutics, Inc. AKBA is a biopharmaceutical company. that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum ...

In this article, we are going to take a look at where Akebia Therapeutics Inc. (NASDAQ:AKBA) stands against other Thursday’s worst-performing stocks. Wall Street’s main indices edged lower on ...

The average one-year price target for Akebia Therapeutics (NASDAQ:AKBA) has been revised to 4.59 / share. This is an increase of 16.13% from the prior estimate of 3.95 dated October 31 ...

Akebia Therapeutics (NASDAQ:AKBA) announced Thursday that it has regained full rights to sell its newly approved kidney disease therapy Vafseo (vadadustat) in the U.S. after its partner CSL Vifor ...

Akebia Therapeutics, Inc.AKBA is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Recently ...

Akebia Therapeutics (NASDAQ:AKBA) shares have traded in a range of $2.5 - $5 since September 2020, and are currently priced at $3.45, giving the biotech a market cap of $552m. Prior to this ...